The Genetics of Primary Biliary Cholangitis: A GWAS and Post-GWAS Update

Genes (Basel). 2023 Feb 3;14(2):405. doi: 10.3390/genes14020405.

Abstract

Primary biliary cholangitis (PBC) is a chronic, progressive cholestatic liver disease in which the small intrahepatic bile ducts are destroyed by autoimmune reactions. Among autoimmune diseases, which are polygenic complex traits caused by the combined contribution of genetic and environmental factors, PBC exhibits the strongest involvement of genetic heritability in disease development. As at December 2022, genome-wide association studies (GWASs) and associated meta-analyses identified approximately 70 PBC susceptibility gene loci in various populations, including those of European and East Asian descent. However, the molecular mechanisms through which these susceptibility loci affect the pathogenesis of PBC are not fully understood. This study provides an overview of current data regarding the genetic factors of PBC as well as post-GWAS approaches to identifying primary functional variants and effector genes in disease-susceptibility loci. Possible mechanisms of these genetic factors in the development of PBC are also discussed, focusing on four major disease pathways identified by in silico gene set analyses, namely, (1) antigen presentation by human leukocyte antigens, (2) interleukin-12-related pathways, (3) cellular responses to tumor necrosis factor, and (4) B cell activation, maturation, and differentiation pathways.

Keywords: disease pathogenesis; disease susceptibility gene; genetic factor; genome-wide association study (GWAS); organ-specific autoimmune disease; polygenic complex trait; post-GWAS study; primary biliary cholangitis (PBC).

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmune Diseases*
  • Cell Differentiation
  • Genome-Wide Association Study
  • Humans
  • Liver Cirrhosis, Biliary* / genetics
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Tumor Necrosis Factor-alpha

Grants and funding

This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science to Yuki Hitomi (22K08065, 19K08413) and Minoru Nakamura (17H04169), Clinical Research from the NHO to Minoru Nakamura, Research Program for Rare/Intractable Diseases provided by the Ministry of Health, Labour, and Welfare of Japan to Minoru Nakamura, and the Takeda Foundation to Yuki Hitomi.